Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma

Hematology/oncology Clinics of North America
Gayathri Anandappa, Ian Chau

Abstract

With further understanding of the biology of gastric and gastroesophageal adenocarcinomas, strides are being made to find effective treatments through novel trial designs. This article focuses on the ongoing trials of drugs targeting specific hallmarks of gastric and gastroesophageal cancers, including oncogene addiction proliferative pathways (fibroblast growth factor receptor 2 amplified tumors), stem cell inhibition, apoptotic induction through claudin inhibitors, and matrix metalloproteinase inhibition. In developing novel therapeutics in treatment of patients with gastroesophageal adenocarcinomas, parallel research efforts to refine target population and biomarkers are crucial, and targeting the tumor genomics and microenvironment may be key in improving overall survival.

Citations

Aug 16, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yelena Y JanjigianDung T Le
Nov 14, 2017·Chemical Biology & Drug Design·Han-Yue QiuYong-Hua Yang
Sep 1, 2017·Expert Review of Gastroenterology & Hepatology·Angela Lopomo, Fabio Coppedè

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.